Skip to main content

Table 2 Associations between NER genetic variants and DFS and OS of Chinese ESCC patients

From: Genetic variants of DNA repair genes predict the survival of patients with esophageal squamous cell cancer receiving platinum-based adjuvant chemotherapy

NER genotypes

No. of patients

DFS

OS

Progression

Univariate analysis

Multivariate analysis*

Death

Univariate analysis

Multivariate analysis*

No. (%)

HR (95 % CI)

P value

HR (95 % CI)

P value

No. (%)

HR (95 % CI)

P value

HR (95 % CI)

P value

ERCC5 rs2094258

           

 CC

108

53 (49.1)

1.00

 

1.00

 

42 (38.9)

1.00

 

1.00

 

 CT

181

128 (70.7)

1.78 (1.29–2.46)

0.0004

1.70 (1.23–2.36)

0.001

118 (65.2)

2.06 (1.45–2.93)

<0.0001

1.98 (1.38–2.83)

0.0002

 TT

55

39 (70.9)

1.72 (1.14–2.61)

0.010

1.63 (1.07–2.48)

0.021

36 (65.5)

2.07 (1.32–2.23)

0.001

2.02 (1.29–3.16)

0.002

 CT+TT

236

167 (70.8)

1.76 (1.30–2.41)

0.0003

1.68 (1.23–2.31)

0.012

154 (65.3)

2.06 (1.46–2.90)

<0.0001

1.99 (1.40–2.81)

0.0001

 Trend test

   

0.002

 

0.0007

  

0.0002

 

0.0005

 CC+CT

289

181 (62.6)

1.00

 

1.00

 

160 (55.4)

1.00

 

1.00

 

 TT

55

39 (70.9)

1.19 (0.84–1.68)

0.331

1.16 (0.82–1.64)

0.415

36 (65.5)

1.28 (0.89–1.84)

0.178

1.29 (0.90–1.86)

0.171

ERCC5 rs2296147

           

 TT

244

160 (65.6)

1.00

 

1.00

 

145 (59.4)

1.00

 

1.00

 

 TC

91

56 (61.5)

0.91 (0.67–1.23)

0.524

0.91 (0.67–1.24)

0.563

49 (53.9)

0.87 (0.63–1.21)

0.411

0.92 (0.66–1.29)

0.603

 CC

9

4 (44.4)

0.52 (0.19–1.42)

0.201

0.49 (0.18–1.34)

0.165

2 (22.2)

0.26 (0.06–1.05)

0.058

0.27 (0.07–1.09)

0.066

 TC+CC

100

60 (60.0)

0.86 (0.64–1.16)

0.333

0.87 (0.64–1.17)

0.345

51 (51.0)

0.80 (0.58–1.10)

0.172

0.84 (0.61–1.16)

0.289

 Trend test

   

0.214

 

0.206

  

0.067

 

0.120

 TT+CT

335

216 (64.5)

1.00

 

1.00

 

194 (57.9)

1.00

 

1.00

 

 CC

9

4 (4.4)

0.54 (0.20–1.45)

0.219

0.51 (0.19–1.37)

0.180

2 (22.2)

0.27 (0.07–1.08)

0.065

0.28 (0.07–1.12)

0.071

ERCC5 rs873601

           

 AA

56

29 (51.8)

1.00

   

22 (39.3)

    

 GA

189

126 (66.7)

1.58 (1.05–2.36)

0.027

1.63 (1.08–2.47)

0.021

112 (59.3)

1.83 (1.16–2.89)

0.010

1.89 (1.19–3.02)

0.008

 GG

99

65 (65.7)

1.56 (1.01–2.42)

0.047

1.51 (0.97–2.34)

0.069

62 (62.6)

1.99 (1.22–3.24)

0.006

1.93 (1.18–3.16)

0.009

 GA+GG

288

191 (66.3)

1.57 (1.06–2.32)

0.024

1.59 (1.06–2.37)

0.024

174 (39.3)

1.89 (1.21–2.94)

0.005

1.91 (1.21–2.99)

0.0005

 Trend test

   

0.084

 

0.146

  

0.011

 

0.021

 AA+GA

245

155 (63.3)

1.00

   

134 (54.7)

1.00

   

 GG

99

65 (65.7)

1.09 (0.82–1.46)

0.536

1.04 (0.77–1.39)

0.803

62 (62.6)

1.23 (0.91–1.67)

0.168

1.18 (0.87–1.60)

0.297

ERCC2 rs238406

           

 GG

102

58 (56.9)

1.00

 

1.00

 

50 (49.0)

1.00

 

1.00

 

 GT

158

101 (63.9)

1.16 (0.84–1.61)

0.361

1.15 (0.83–1.60)

0.403

87 (55.1)

1.21 (0.85–1.71)

0.256

1.23 (0.87–1.75)

0.247

 TT

84

61 (72.6)

1.59 (1.11–2.28)

0.012

1.56 (1.08–2.24)

0.017

59 (70.2)

1.76 (1.21–2.57)

0.003

1.72 (1.18–2.52)

0.005

 GT+TT

242

162 (66.9)

1.29 (0.96–1.75)

0.094

1.28 (0.94–1.73)

0.115

146 (60.3)

1.38 (1.00–1.91)

0.049

1.40 (1.01–1.93)

0.044

 Trend test

   

0.013

 

0.019

  

0.004

 

0.005

 GG+GT

260

159 (61.2)

1.00

 

1.00

 

137 (52.7)

1.00

 

1.00

 

 TT

84

61 (72.6)

1.45 (1.08–1.95)

0.014

1.43 (1.06–1.93)

0.020

59 (70.2)

1.57 (1.15–2.13)

0.004

1.52 (1.12–2.03)

0.008

XPC rs1870134

           

 GG

181

111 (61.3)

    

94 (51.9)

1.00

 

1.00

 

 GC

144

95 (66.0)

1.08 (0.82–1.41)

0.605

1.10 (0.83–1.46)

0.495

89 (61.8)

1.21(0.91–1.62)

0.192

1.25 (0.93–1.68)

0.137

 CC

18

14 (73.7)

1.67 (0.96–2.92)

0.070

1.41 (0.80–2.48)

0.235

13 (68.4)

1.77 (0.99–3.17)

0.053

1.52 (0.84–2.75)

0.164

 GC+CC

163

109 (66.9)

1.13 (0.87–1.47)

0.374

1.13 (0.87–1.48)

0.356

102 (62.6)

1.26 (0.96–1.67)

0.101

1.28 (0.96–1.70)

0.088

 Trend test

   

0.171

 

0.242

  

0.045

 

0.066

 GG+GC

325

206 (63.4)

1.00

 

1.00

 

183 (56.3)

1.00

 

1.00

 

 CC

19

14 (73.7)

1.62 (0.94–2.79)

0.081

1.35 (0.78–2.35)

0.285

13 (68.4)

1.62 (0.92–2.85)

0.093

1.38 (0.78–2.45)

0.274

XPC rs2228001

           

 TT

139

87 (62.6)

1.00

 

1.00

 

77 (55.4)

1.00

 

1.00

 

 TG

155

101 (65.2)

1.10 (0.82–1.46)

0.537

1.19 (0.89–1.59)

0.250

89 (57.4)

1.05 (0.77–1.42)

0.758

1.15 (0.84–1.57)

0.377

 GG

50

32 (64.0)

1.18 (0.79–1.77)

0.418

1.29 (0.85–1.96)

0.238

30 (60.0)

1.25 (0.82–1.91)

0.295

1.36 (0.88–2.12)

0.171

 TG+GG

205

133 (64.9)

1.12 (0.85–1.46)

0.432

1.21 (0.92–1.59)

0.181

119 (58.0)

1.09 (0.82–1.46)

0.539

1.19 (0.89–1.60)

0.241

 Trend test

   

0.713

 

0.593

  

0.386

 

0.282

 TT+TG

294

188 (64.0)

1.00

 

1.00

 

166 (56.5)

1.00

 

1.00

 

 GG

50

32 (64.0)

0.89 (0.61–1.29)

0.531

1.17 (0.80–1.73)

0.418

30 (60.0)

1.22 (0.83–1.80)

0.313

1.26 (0.84–1.89)

0.263

NRG**

           

 0

37

18 (48.7)

1.00

 

1.00

 

12 (32.4)

1.00

 

1.00

 

 1

63

30 (47.6)

0.97 (0.54–1.17)

0.789

1.09 (0.60–1.98)

0.920

25 (39.7)

1.22 (0.61–1.42)

0.578

1.38 (0.69–2.79)

0.365

 2

187

127 (67.9)

1.32 (1.03–1.69)

0.030

1.32 (1.03–1.71)

0.021

115 (61.5)

1.53 (1.14–2.06)

0.005

1.55 (1.15–2.10)

0.005

 3

57

45 (79.0)

1.34 (1.12–1.61)

0.002

1.34 (1.11–1.61)

0.0009

44 (77.2)

1.51 (1.22–1.87)

<0.0002

1.51 (1.22–1.88)

0.0002

 Trend test

   

<0.0001

 

<0.0001

  

<0.0001

 

<0.0001

 0–1

100

48 (48.0)

1.00

 

1.00

 

37 (37.0)

1.00

 

1.00

 

 2–3

244

172 (70.5)

1.69 (1.22–2.35)

0.002

1.67 (1.20–2.34)

0.003

159 (65.2)

1.84 (1.32–2.58)

0.0004

1.77 (1.29–2.50)

0.001

  1. * Adjusted by all the demographic and clinical variables in Table 1 including age, sex, smoking, drinking, TNM stage, vessel invasion, neural invasion, lymphadenectomy
  2. ** NRG include ERCC5 rs2094258 CT/TT, re873061GA/GG, ERCC2 rs238406 TT